69 related articles for article (PubMed ID: 25256412)
1. CXCR7 expression correlates with tumor depth in cutaneous squamous cell carcinoma skin lesions and promotes tumor cell survival through ERK activation.
Hu SC; Yu HS; Yen FL; Chen GS; Lan CC
Exp Dermatol; 2014 Dec; 23(12):902-8. PubMed ID: 25256412
[TBL] [Abstract][Full Text] [Related]
2. CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway.
Zhu B; Xu D; Deng X; Chen Q; Huang Y; Peng H; Li Y; Jia B; Thoreson WB; Ding W; Ding J; Zhao L; Wang Y; Wavrin KL; Duan S; Zheng J
Stem Cells; 2012 Nov; 30(11):2571-83. PubMed ID: 22987307
[TBL] [Abstract][Full Text] [Related]
3. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.
Zieger-Naumann K; Kuhl F; Engele J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418
[TBL] [Abstract][Full Text] [Related]
4. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas.
Tarnowski M; Grymula K; Reca R; Jankowski K; Maksym R; Tarnowska J; Przybylski G; Barr FG; Kucia M; Ratajczak MZ
Mol Cancer Res; 2010 Jan; 8(1):1-14. PubMed ID: 20068066
[TBL] [Abstract][Full Text] [Related]
5. Exploring the CXCR4/CXCR7/CXCL12 Axis in Primary Desmoid Tumors.
Baccalini EA; Renne SL; Colombo P; Pasqualini F; Quagliuolo VL; Cananzi FCM; Grizzi F; Borroni EM
Anticancer Agents Med Chem; 2023; 23(20):2248-2253. PubMed ID: 36748819
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12.
Del Molino Del Barrio I; Wilkins GC; Meeson A; Ali S; Kirby JA
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30441765
[TBL] [Abstract][Full Text] [Related]
7. Molecular insights into intrinsic transducer-coupling bias in the CXCR4-CXCR7 system.
Sarma P; Carino CMC; Seetharama D; Pandey S; Dwivedi-Agnihotri H; Rui X; Cao Y; Kawakami K; Kumari P; Chen YC; Luker KE; Yadav PN; Luker GD; Laporte SA; Chen X; Inoue A; Shukla AK
Nat Commun; 2023 Aug; 14(1):4808. PubMed ID: 37558722
[TBL] [Abstract][Full Text] [Related]
8. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
Maussang D; Mujić-Delić A; Descamps FJ; Stortelers C; Vanlandschoot P; Stigter-van Walsum M; Vischer HF; van Roy M; Vosjan M; Gonzalez-Pajuelo M; van Dongen GA; Merchiers P; van Rompaey P; Smit MJ
J Biol Chem; 2013 Oct; 288(41):29562-72. PubMed ID: 23979133
[TBL] [Abstract][Full Text] [Related]
9. CXCR7 silencing attenuates cell adaptive response to stromal cell derived factor 1α after hypoxia.
Liu S; Jia X; Li C; Han X; Yan W; Xing Y
PLoS One; 2013; 8(1):e55290. PubMed ID: 23383139
[TBL] [Abstract][Full Text] [Related]
10. Demethylation in promoter region of severely damaged hepatocytes enhances chemokine receptor CXCR4 gene expression.
Ito C; Haraguchi R; Ogawa K; Iwata M; Kitazawa R; Takada Y; Kitazawa S
Histochem Cell Biol; 2023 Nov; 160(5):407-418. PubMed ID: 37532885
[TBL] [Abstract][Full Text] [Related]
11. Tumor Suppressive Function of NQO1 in Cutaneous Squamous Cell Carcinoma (SCC) Cells.
Zhang QL; Li XM; Lian DD; Zhu MJ; Yim SH; Lee JH; Jiang RH; Kim CD
Biomed Res Int; 2019; 2019():2076579. PubMed ID: 31886179
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Immune System in Cutaneous Squamous Cell Carcinoma.
Bottomley MJ; Thomson J; Harwood C; Leigh I
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022866
[TBL] [Abstract][Full Text] [Related]
13. The Novel Checkpoint Target Lymphocyte-Activation Gene 3 Is Highly Expressed in Cutaneous Squamous Cell Carcinoma.
Dany M; Doudican N; Carucci J
Dermatol Surg; 2023 Dec; 49(12):1112-1115. PubMed ID: 37962130
[TBL] [Abstract][Full Text] [Related]
14. CXCR7 promotes the migration of fibroblasts derived from patients with acquired laryngotracheal stenosis by NF-κB signaling.
Xu M; Hu B; Chen J; Zhao L; Wang J; Li X
Transl Pediatr; 2023 Sep; 12(9):1634-1645. PubMed ID: 37814711
[TBL] [Abstract][Full Text] [Related]
15. Plasma Treatment Limits Cutaneous Squamous Cell Carcinoma Development In Vitro and In Vivo.
Pasqual-Melo G; Nascimento T; Sanches LJ; Blegniski FP; Bianchi JK; Sagwal SK; Berner J; Schmidt A; Emmert S; Weltmann KD; von Woedtke T; Gandhirajan RK; Cecchini AL; Bekeschus S
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708225
[TBL] [Abstract][Full Text] [Related]
16. A prospective cohort study evaluating m
Lazaroff J; Duan GY; Verghese M; Bertacchi B; Yang S; He YY; Bolotin D
J Am Acad Dermatol; 2023 Nov; 89(5):1083-1084. PubMed ID: 37516358
[No Abstract] [Full Text] [Related]
17. Survival analyses in cutaneous squamous cell carcinoma: accounting for both competing risks and repeated measures.
Nikahd M; Hyer M; Ruiz ES; Shahwan KT; Carr DR
Arch Dermatol Res; 2023 Nov; 316(1):3. PubMed ID: 37982998
[No Abstract] [Full Text] [Related]
18. Correction: IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.
Qiao Y; Zhang C; Li A; Wang D; Luo Z; Ping Y; Zhou B; Liu S; Li H; Yue D; Zhang Z; Chen X; Shen Z; Lian J; Li Y; Wang S; Li F; Huang L; Wang L; Zhang B; Yu J; Qin Z; Zhang Y
Oncogene; 2023 Oct; 42(44):3287-3288. PubMed ID: 37723312
[No Abstract] [Full Text] [Related]
19. Role of chemokines in renal cell carcinoma.
Parihar JS; Tunuguntla HS
Rev Urol; 2014; 16(3):118-21. PubMed ID: 25337041
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
